Novartis Pays Enanta $34M Up Front for Worldwide Rights to HCV NS5A Inhibitors – Genetic Engineering News

Anti-infectives specialist Enanta is developing HCV protease, polymerase, and cyclophilin-based inhibitors and has generated a class of macrolide antibiotics, called bicyclolides, which it claims can overcome bacterial resistance. The firm …

Leave a Reply

Your email address will not be published.